Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status by Mark Awad, Mizuki Nishino, Mehmet Altan, Biagio Ricciuti, Fangxin Hong, Matthew Hellmann, John V Heymach, Joao V Alessi, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter

Get full text

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC by Alexandre Reuben, Mehmet Altan, Latasha Little, Jianjun Zhang, Ajay Sheshadri, Hai T Tran, Mara B Antonoff, Stephen G Swisher, John V Heymach, Saumil Gandhi, Natalie Vokes, Ziyi Li, Ruoxing Li, Runzhe Chen, Joshua Baguley, Jefferson Sinson, Greg Lizee

Get full text

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial by Chad Tang, Patricia de Groot, James Welsh, Hari Menon, Dawei Chen, Vivek Verma, Mehmet Altan, Kenneth Hess, John V Heymach, Quynh-Nhu Nguyen, Rejani Varghese, Nathan I Comeaux, George Simon, Ferdinandos Skoulidis, Joe Y Chang, Vasiliki Papdimitrakopoulou, Steven H Lin

Get full text

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively i... by Jing Wang, Ignacio I Wistuba, Alexandre Reuben, Chantale Bernatchez, Tina Cascone, Jianjun Zhang, Boris Sepesi, Edwin R Parra, Ara A Vaporciyan, Kyle G Mitchell, Lixia Diao, Tatiana Karpinets, Marcelo V Negrao, Hai T Tran, Erin M Corsini, Lorenzo Federico, Hitoshi Dejima, Alejandro Francisco-Cruz, Mara B Antonoff, Stephen G Swisher, John V Heymach, Don L Gibbons, Cara L Haymaker

Get full text